The effects of a new chromenyl-methylenethiazolidine- 2,4-dione in alleviating oxidative stress in a rat model of streptozotocininduced diabetes

Abstract

Type 1 diabetes mellitus (T1DM) is caused by the insulin deficiency resulting from the progressive destruction of pancreatic Β cells. Thiazolidine-2,4-diones (TZDs) activate the peroxisome proliferator-activated receptor-? (PPAR?) and enhance the actions of insulin. 5-((6-methyl-4-oxo-4Hchromen- 3-yl)methylene)-3-(2-(4-nitrophenyl)-2-oxoethyl)-thiazolidine-2,4-dione (TZDd) is a heterocyclic derivative synthesized in our laboratory. The purpose of this study was to examine whether TZDd has hypoglycemic and antioxidant effects in diabetic rats. Its effects were compared with those of quercetin (Que), a potent antioxidant, and with pioglitazone (Pio), a well-known antidiabetic drug. Type 1 DM was induced in Wistar rats by the intraperitoneal administration of streptozotocin (STZ) (60 mg/kg). The non-diabetic and diabetic rats were treated with Que (30 mg/kg/day), pioglitazone (30 mg/kg/day), or TZDd (30 mg/kg/day), for 5 weeks. The serum levels of malondialdehyde (MDA) and protein carbonyl (PC) groups, and the superoxide dismutase (SOD) and catalase (CAT) activities in the blood were then assessed. The results indicated that the TZDd decreased the blood oxidative stress parameters in the treated diabetic rats, compared to Que and pioglitazone. In conclusion, the hypoglycemic and antioxidant effects of TZDd in diabetic rats, suggest its therapeutic properties for the clinical treatment of T1DM.